Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Receivables (2016 - 2025)

Apyx Medical (APYX) has disclosed Receivables for 16 consecutive years, with $17.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 7.53% year-over-year to $17.1 million, compared with a TTM value of $17.1 million through Dec 2025, up 7.53%, and an annual FY2025 reading of $17.1 million, up 7.53% over the prior year.
  • Receivables was $17.1 million for Q4 2025 at Apyx Medical, up from $13.0 million in the prior quarter.
  • Across five years, Receivables topped out at $17.1 million in Q4 2025 and bottomed at $8.8 million in Q1 2021.
  • Average Receivables over 5 years is $12.3 million, with a median of $12.4 million recorded in 2022.
  • The sharpest move saw Receivables skyrocketed 68.45% in 2021, then fell 26.01% in 2022.
  • Year by year, Receivables stood at $13.5 million in 2021, then dropped by 20.86% to $10.7 million in 2022, then skyrocketed by 35.72% to $14.5 million in 2023, then rose by 9.34% to $15.9 million in 2024, then grew by 7.53% to $17.1 million in 2025.
  • Business Quant data shows Receivables for APYX at $17.1 million in Q4 2025, $13.0 million in Q3 2025, and $11.2 million in Q2 2025.